Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Evofem Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Evofem Biosciences, Inc.

EVFM

Evofem Biosciences, Inc.

About Evofem Biosciences, Inc.

Evofem Biosciences is a biopharmaceutical company specializing in women’s sexual and reproductive health. Its core products include PHEXXI, a hormone-free, prescription vaginal gel for contraception, and SOLOSEC, an oral treatment for bacterial vaginosis and trichomoniasis. The company focuses on innovative, woman-controlled solutions, leveraging strong physician relationships and strategic partnerships to expand access in the U.S. and global markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Evofem Biosciences, Inc.

1
1
Evofem Biosciences, Inc. Evofem Biosciences Reports $5.5 Million Net Loss in Q1 2026 Amid Revenue Growth

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Evofem Biosciences, Inc. Evofem Biosciences Reports 4% Increase in Net Product Sales Amid Financial Challenges

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Evofem Biosciences, Inc. Evofem Biosciences Reports Q3 2025 Financial Results with $1.6M Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Evofem Biosciences, Inc. Evofem Biosciences Reports Q2 2025 Financial Results with $1.8M Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Evofem Biosciences, Inc. Evofem Biosciences Reports Net Income of $956,000 in Q1 2025, Down from $4.8M Loss in Q1 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Evofem Biosciences, Inc. Evofem Biosciences Reports $8.9 Million Net Loss for 2024 Amid Revenue Growth and Ongoing Legal Disputes

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Evofem Biosciences, Inc. Evofem Biosciences Reports Mixed Q3 Results, Net Loss, and Liquidity Concerns

Via official filing (AI summary) | over 1 year ago | 0 comments